Amendment No. 2 to the Other Transaction for Advanced Research (OTAR) between the Company and the United States of America Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority, concerning Pre-exposure Prophylactic Monoclonal Antibodies for the Prevention of Influenza Illness and Medical Countermeasures for Other Emerging Pathogens of Pandemic Potential (Agreement No. 75A50122C00081, Amendment No. P0000
Contract Categories:
Business Operations
- Development Agreements
EX-10.3 4 a20241104-q310qex103.htm EX-10.3 Document
Exhibit 10.3
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED.
Other Transaction Agreement No. 75A50122C00081
Amendment No. P00002
OTHER TRANSACTION FOR ADVANCED RESEARCH (OTAR)
Agreement No.: 75A50122C00081
BETWEEN
VIR BIOTECHNOLOGY, INC
1800 OWENS STREET, SUITE 900 SAN FRANCISCO, CA 94158
AND
THE UNITED STATES OF AMERICA DEPARTMENT OF HEALTH AND HUMAN SERVICES
BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY
330 INDEPENDENCE AVENUE, SW G640 WASHINGTON, DC 20201
CONCERNING
Pre-exposure prophylactic monoclonal antibodies for the prevention of influenza illness and medical countermeasures for other emerging pathogens of pandemic potential
Agreement No.: 75A50122C00081
Amendment No. P00002
Effective Date of Amendment: This Amendment No. P00002 (the “Amendment”) will be effective upon last signature in Section III.
Total Amount of the Agreement is unchanged at [***].
Government Share of Total Amount of the Agreement remains unchanged and is not to exceed
$1,000,000,000.
Recipient Share of Total Amount of the Agreement is unchanged at [***].
Current Government commitment is uchanged at $116,300,401.
Current Recipient commitment is unchanged at [***].
Authority: Section 319L of the Public Health Service Act, 42 USC 247d-7e.
OT No. 75A50122C00081 Page 1 | ||
Other Transaction Agreement No. 75A50122C00081
Amendment No. P00002
Line of Accounting and Appropriation:
CLIN | PRISM line item | Title | Requisition (OS) | Appropriation Year | CAN | Object Class | Amt. (Govt Share) | Changed or Unchanged | ||||||||||||||||||
0001 | 0001 | Base Period: VIR-2482- 4002 PENNISULA Phase 2 study | [***] | 2022 | [***] | 25103 | $50,000,000.00 | Unchanged | ||||||||||||||||||
0001 | 0001 | Base Period: VIR-2482- 4002 PENNISULA Phase 2 study | [***] | 2022 | [***] | 25103 | $5,000,000.00 | Unchanged | ||||||||||||||||||
0001 | 0001 | VIR-2482-4002 PENNISULA Phase 2 study | [***] | 2023 | [***] | 25106 | $11,249,523.00 | Unchanged | ||||||||||||||||||
0013 | 0002 | Option 12- FASTx VIR- 7229 | [***] | 2023 | [***] | 25106 | $40,000,000.00 | Unchanged | ||||||||||||||||||
0014 | 0003 | Option 12- FASTx [***] | [***] | 2023 | [***] | 25106 | $2,976,862.50 | Unchanged | ||||||||||||||||||
0014 | 0004 | Option 12- FASTx [***] | [***] | 2023 | [***] | 25106 | $7,074,015.50 | Unchanged | ||||||||||||||||||
| Total | $116,300,401.00 | Unchanged | ||||||||||||||||||||||||
I.AMENDMENT PURPOSE: The purpose of this amendment is to:
a.Revise the language in Amendment 1, Amendment Changes, paragraph F From:
[***]
To:
[***]
b.Update the term of the agreement in line with Option 12 period of performance.
II.AMENDMENT CHANGES:
a.[***]
OT No. 75A50122C00081 Page 2 | ||
Other Transaction Agreement No. 75A50122C00081
Amendment No. P00002
b.Article II: Term, Section A, Paragraph 1 shall be deleted and replaced with “The Term of this Agreement commences upon the effective date of September 30, 2022, and extends through July 15, 2027.”
III.EXECUTION
Capitalized terms not otherwise defined herein shall have their respective meanings in the Agreement. Except as provided in this Amendment, all terms and conditions of the Agreement, unless previously changed, remain unchanged and in full force and effect.
Acknowledged, accepted, and agreed for:
Vir Biotechnology, Inc | U.S. Department of Health & Human Services | |||||||
Administration for Strategic Preparedness & Response | ||||||||
Biomedical Advanced Research & Development Authority | ||||||||
| BY: | BY: Date: 2024.01.18 18:22:19 -05'00' | |||||||
NAME: MARIANNE DE BACKER, M.SC., PH.D., MBA | NAME: [***] | |||||||
TITLE: Chief Executive Officer | TITLE: [***] | |||||||
DATE: January 17, 2024 | DATE: January 18, 2024 | |||||||
OT No. 75A50122C00081 Page 3 | ||
DocuSign Envelope ID: 26D43BF3-6C19-4AFA-82D1-E8DD0186D9AC | ||
Other Transaction Agreement No. 75A50122C00081
Amendment No. P00002
Attachment A: [***]
OT No. 75A50122C00081 Page 30 | ||
